A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 962 participants.
Also called NCT06192108
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 962 participants
- Sponsor
- Registry
-
NCT06192108
-
- Other papers using this trial's data
- Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, China, Germany, Mexico, Poland, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT06192108. Randomized; no masking; primary purpose treatment. Start 2024-01-10 (actual); primary completion 2025-09-26 (actual). Results posted on 2026-10-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
- Acronym
- ACHIEVE-2
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06192108- Content hash
d843e7e3e89930ac63453c68c3ca3e71f5a147e8041c8e15c39989b36d0c88f6